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Abstract
Background: Treatment of patients with non-metastatic, locally advanced rectal cancer (LARC) includes pre-operative
chemoradiation, total mesorectal excision (TME) and post-operative adjuvant chemotherapy. This trimodality treatment
provides local tumor control in most patients; but almost one-third ultimately die from distant metastasis. Most
survivors experience significant impairment in quality of life (QoL), due primarily to removal of the rectum. A current
challenge lies in identifying patients who could safely undergo rectal preservation without sacrificing survival benefit
and QoL.
Methods/Design: This multi-institutional, phase II study investigates the efficacy of total neoadjuvant therapy (TNT)
and selective non-operative management (NOM) in LARC. Patients with MRI-staged Stage II or III rectal cancer
amenable to TME will be randomized to receive FOLFOX/CAPEOX: a) before induction neoadjuvant chemotherapy
(INCT); or b) after consolidation neoadjuvant chemotherapy (CNCT), with 5-FU or capecitabine-based chemoradiation.
Patients in both arms will be re-staged after completing all neoadjuvant therapy. Those with residual tumor at the
primary site will undergo TME. Patients with clinical complete response (cCR) will receive non-operative management
(NOM). NOM patients will be followed every 3 months for 2 years, and every 6 months thereafter. TME patients will be
followed according to NCCN guidelines. All will be followed for at least 5 years from the date of surgery or—in
patients treated with NOM—the last day of treatment.
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Discussion: The studies published thus far on the safety of NOM in LARC have compared survival between select
groups of patients with a cCR after NOM, to patients with a pathologic complete response (pCR) after TME. The current
study compares 3-year disease-free survival (DFS) in an entire population of patients with LARC, including those with
cCR and those with pCR. We will compare the two arms of the study with respect to organ preservation at 3 years,
treatment compliance, adverse events and surgical complications. We will measure QoL in both groups. We will
analyze molecular indications that may lead to more individually tailored treatments in the future. This will be the first
NOM trial utilizing a regression schema for response assessment in a prospective fashion.
Trial registration: NCT02008656
Keywords: Rectal cancer, Non-operative management, Chemoradiation therapy, Total mesorectal excision. Total
neoadjuvant therapy, Clinical complete response, Pathologic complete response
Background
Standard treatment of patients with non-metastatic, lo-
cally advanced rectal cancer (LARC) includes preopera-
tive chemoradiation (CRT), total mesorectal excision
(TME) and postoperative adjuvant chemotherapy (ACT)
[1]. This intensive tri-modal therapy provides local con-
trol of disease in a majority of patients, and has been
adopted as the standard of care in the United States.
However, nearly one-third of patients die from distant
metastasis (DM) [2], which presumably develops from
micrometastases that are clinically occult at the time of
surgery. Furthermore, most survivors experience func-
tional sequelae due to removal of the rectum, which sig-
nificantly impairs their quality of life (QoL) [3]. Thus,
current challenges in the treatment of LARC are two-
fold: 1) Prolongation of survival by reducing the risk of
DM; 2) Preservation of QoL in surviving patients by
safely avoiding rectal resection.
ACT in LARC patients consists of 4 months of 5-
Fluorouracil (5-FU), Leucovorin and Oxaliplatin (FOL-
FOX), or Capecitabine and Oxaliplatin (CapeOx), starting
within 8 weeks after surgery. Unfortunately, more than
one-third of eligible patients never start CT because they
develop post-operative complications, are too debilitated
following surgery, or simply refuse it. Furthermore, less
than half of eligible patients receive the full course of
FOLFOX [4,5]. It has been proposed that delivery of all
CT before rather than after surgery may increase treat-
ment compliance [6,7]. Through early initiation of optimal
systemic CT, this approach may enhance the effectiveness
of CT in eradicating micrometastasis, and ultimately im-
prove survival. Delivery of systemic chemotherapy before
surgery has other potential benefits, such as improving
primary tumor response and reducing the interval to di-
verting loop ileostomy (DLI) takedown. Our institution
has experience with delivery of CT at systemic doses be-
fore TME, either before or after CRT, in patients with
LARC. We recently reported excellent safety profile and
treatment compliance in a series of 32 LARC patients
treated with FOLFOX before CRT. [8] All patients who
underwent TME had an R0 resection, and nearly half had
a tumor response greater than 90 %, including 30 % who
had either a pathologic complete response (pCR) or a
clinical complete response (cCR). The Timing of Rectal
Cancer Response to Chemoradiation Trial (TIMING trial,
NIH NCT00335816), which completed accrual in 2012,
showed that delivering 2, 4, or 6 cycles of FOLFOX after
CRT—a concept known as consolidation chemotherapy
(CNCT)—in LARC patients increased pCR rates to 25 %,
30 %, and 38 %, respectively, compared to CRT alone
(18 %), without an associated increase in adverse events or
surgical complications. Notably, 80 % of patients received
CNCT without interruption [9]. These data suggest that
the use of both CRT and CT before surgery–a concept
known as total neoadjuvant therapy (TNT)—improves
compliance with systemic CT when compared to postop-
erative ACT, and may increase tumor response.
A proportion of patients with LARC have a pCR to
CRT. It is widely acknowledged that patients with a pCR
have lower rates of tumor recurrence, and improved sur-
vival, compared to those who do not [10,11]. This leads
us to question whether there is a durable benefit to re-
moving the rectum in patients with a pCR. Curing the
cancer without removing the rectum could potentially
decrease long-term functional problems, and preserve
QoL [12].
This randomized phase II trial is designed to test the
hypothesis that patients with LARC treated with TNT
and TME, or NOM, will have improved 3-year DFS
compared to patients treated with CRT, TME and ACT.
This study investigates the efficacy of two neoadjuvant
chemotherapy (NCT) schedules combined with CRT, in
an effort to maximize the proportion of patients with
LARC who may be cured without undergoing radical
surgery. Patients with LARC who are considered candi-
dates for a low anterior resection, a coloanal anasto-
mosis (CAA) or abdominoperineal excision (APE) will
be randomized to receive NCT, either a) before (Induc-
tion arm) or b) after (Consolidation arm) CRT. Patients
will be restaged 8 (+/- 4) weeks after completing all
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neoadjuvant therapy. Those with incomplete tumor re-
sponse will undergo TME. Patients with cCR will be ob-
served, and only those showing signs of tumor relapse
during follow-up will undergo TME. We have also put
forth a novel regression schema to improve the uni-
formity of response assessment that will be tested and
validated in a prospective fashion. To add value, we will
measure QoL in patients treated with TNT and TME in
comparison to patients treated with TNT alone. Add-
itionally, we will compare induction chemotherapy
(INCT) to consolidation chemotherapy (CNCT) with
respect to organ preservation at 3 years, treatment com-
pliance, adverse events and surgical complications.
Methods/design
Study design
This is a two-arm, randomized, multi-institutional phase
II study investigating the efficacy of TNT and selective
NOM in LARC patients. Patients with MRI-staged T2-3,
N0 or T-any, N1,2 rectal cancer amenable to TME will
be randomized to receive FOLFOX/CapeOx before or
after 5-FU or capecitabine-based CRT. The study
schema is presented in Fig. 1.
Study objectives
The primary objective of the study is to evaluate 3-year
recurrence-free survival (RFS) in patients managed with
INCT or CNCT, CRT and selective NOM, compared
with standard historical controls managed with CRT and
TME followed by CT. Secondarily, this study seeks to: a)
compare outcomes between patients in the two study
arms with respect to rates of organ preservation, compli-
ance with the neoadjuvant protocol, and adverse events;
and b) measure patient-reported functional outcomes
and QoL in patients with LARC treated with NCT, CRT
and NOM, and compare these to patients treated with
TME.
Correlative studies will be completed to: a) investigate
the diagnostic performance of conventional and diffusion-
weighted magnetic resonance imaging (DW-MRI) in
Fig. 1 Trial schema. MSKCC-based multi-institutional, Phase II trial schema underway to test the feasibility of incorporating a NOM approach
to the multimodality treatment of rectal cancer. This study will evaluate the 3-year DFS in LARC patients treated with CRT plus induction or
consolidation chemotherapy and TME or NOM (https://clinicaltrials.gov/ct2/show/NCT02008656?term=NCT02008656&rank=1)
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identifying patients with LARC who are treated with NCT
and CRT, who may benefit from NOM; b) evaluate the
feasibility of using circulating tumor DNA and micro-RNA
(miRNA) profiles in plasma to monitor tumor response; c)
profile rectal cancers treated with NCT and CRT using
next-generation sequencing; and d) investigate molecular
mechanisms of tumor resistance to neoadjuvant therapy.
Trial organization
The majority of the rectal cancer consortium members
(Fig. 2) were actively involved in a previous multicenter
R01 NCI-funded project (1R01 CA090559-07): “The
Timing of Rectal Cancer Response to Chemoradiation”
(TIMING Trial; NIH NCT00335816; see recent work in
The Lancet Oncology, PMID: 26187751) [9]. Each of these
sites has been actively involved in the study, and each site
has a proven ability to accrue patients and treat them
according to the protocol.
Coordination and monitoring
Memorial Sloan Kettering Cancer Center (MSKCC) is
responsible for overseeing all fiscal and administrative
arrangements with the consortium. The MSKCC Office
of Clinical Research includes a Multicenter Protocol
Group that provides regulatory and administrative sup-
port, and a Clinical Research Quality Assurance group
responsible for auditing and monitoring investigator-
initiated protocols. Participating sites will be monitored
on an ongoing basis to ensure good data management,
HIPAA compliance, and appropriate use of funds, and to
address any local administrative challenges that may hin-
der recruitment. Monthly conference calls are instituted
to discuss administrative and clinical updates. A monthly
project update will be distributed to all Principal Investi-
gators, Coordinators, and project affiliates. In addition,
individual site training and new staff orientations will be
offered throughout the year. For quality control pur-
poses, an annual review will be performed to assess each
site with respect to matters of recruitment, fiscal man-
agement, and data quality. Low-accruing sites will be
evaluated to ensure that they have adequate staff, clear
communication channels, and a screening and recruit-
ment plan in place.
Ethics, informed consent and safety
The Institutional Review Board (IRB) of MSKCC ap-
proved the final protocol, and the appropriate approvals
have been obtained by each participating site. Physicians
Fig. 2 Nonoperative management trial contributors. A map of the United States is shown to demonstrate the multiple institutions involved in
this described Phase II trial determining the feasibility of incorporating a NOM approach to the multimodality treatment of LARC patients
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qualified to conduct the informed consent process must
be certified in the protection of human subjects for re-
search. Before protocol-specified procedures are carried
out, investigators or their staffs will explain to patients
the full details of the protocol and study procedures, as
well as the risks involved, prior to their inclusion in the
trial. Patients will also be informed that they are free to
withdraw from the study at any time. All patients must
sign an IRB-approved consent form indicating their con-
sent to participate. This consent form will meet the re-
quirements of the Code of Federal Regulations and the
Institutional Review Boards of all participating centers.
The consent form includes the nature and objectives,
potential toxicities and benefits, of the intended study;
the required length of therapy and the likely follow-up;
alternatives to the proposed therapy (including available
standard and investigational therapies); supportive care;
the name(s) of the investigator(s) responsible for the
protocol; the right of the patient to accept or refuse
treatment, or to withdraw from the study.
Patient safety is of utmost importance. To ensure that
patients are not put at undue risk, stopping guidelines and
vigilant monitoring practices are in place. Safety will be
assessed through documentation of adverse events during
TNT and after surgery. Adverse events will be graded ac-
cording to NCI CTCAE version 4, and surgical complica-
tions will be graded according to the Clavien-Dindo
Classification [13]. Serious adverse events (SAEs) will be
reported to the Institutional Review Board and recorded
electronically.
To protect patients treated non-operatively against the
risk of local tumor progression during follow-up, we will
monitor continuously for resection with positive margins
(R1 resection) based on repeated significance level. To
protect patients against the risk of tumor progression,
we will conduct an interim evaluation with clinical exam
and radiology studies during neoadjuvant treatment.
Patients with diagnosis of tumor progression during
treatment will be removed from the study and treated
according to standard of care. These cases will be
reviewed by the Data and Safety Monitoring Committee.
We will regularly monitor for adverse events and surgical
complications. The results will be reviewed periodically by
the Data and Safety Monitoring Committee to protect
against the risk of increased adverse events and surgical
complications.
The Principle Investigator (PI), Co-Investigators, research
manager (KA), research project coordinator, and research
service associate will be responsible for ensuring that all
consent forms and electronic data gathered during the
course of the study are stored in locked cabinets, a secure
database, or password-protected HIPAA-approved elec-
tronic files. This applies to all consortium sites, and the
MSKCC PI will be responsible for overseeing compliance.
Remote monitoring and auditing will be performed on all
consortium sites to ensure compliance. Clinical information
will be entered into a HIPAA-compliant, confidential,
password-protected clinical database at MSKCC, which
only the PI, research manager, research project coordinator,
and research service associate will be able to access. The re-
search records will not be included in the patient’s hospital
medical record.
Statistical analyses in the context of the Specific Aims
The goal of Specific Aim 1 is to evaluate 3-year RFS in
patients managed with INCT or CNCT, CRT and select-
ive NOM, compared with standard historical controls
treated with CRT and TME followed by ACT. We
hypothesize that 85 % of patients with LARC treated
with TNT and selective NOM will be alive and free of
disease at 3 years. The 3-year disease-free survival (DFS)
for similar patients (stage II/III LARC within 6 cm from
the anal verge) treated according to the standard of care
(CRT, TME, and ACT) is 75 % [10]. In this trial, each
arm is designed as a single-stage study that discriminates
between 3-year DFS rates of 75 % (historical control)
and 85 % (study groups). For our power calculation, we
assume uniform accrual over time and an exponential
distribution for time to death. Using the approach pro-
posed by Lawless (1982) [14], for 80 % power, a type I
error of 5 %, and a one-sided test, we will require 101
patients per arm, accrued over a 4-year period, with an
additional 3 years of follow-up. With a sample size of
101 patients, we will consider the trial worthy of further
study if the 3-year DFS rate exceeds .82 (the upper crit-
ical value). We anticipate about 10 % loss to follow-up,
and will recruit an additional 10 patients per arm to ac-
count for this. Patient accrual is expected to take 4 years,
with approximately 5 patients accrued per month.
The goal of Specific Aim 2 is to compare outcomes in pa-
tients treated on the two arms of this study, with respect to
rates of organ preservation, compliance with the neoadju-
vant protocol, and adverse events. If both arms meet the
endpoint in Specific Aim 1, we plan to use NOM rate to
determine the more promising regimen using a “pick the
winner” strategy. We will calculate the proportion of pa-
tients treated with NOM who are alive and free of disease
3 years following the start of the study. We will require at
least 20 NOM patients in each arm to employ the following
strategy: If there is a difference of 5 NOM patients between
arms, the arm with more NOM patients will be deemed
the winner. With 101 patients in each arm, 20 % NOM in
patients treated with INCT and 30 % in patients treated
with CNCT, we will have an 83 % probability of selecting
CNCT, a 1 % probability of selecting INCT, and a 16 %
probability of considering the study inconclusive. In
addition, we will calculate therapy compliance using the fol-
lowing measures: number of days RT was held, the number
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of RT delays of ≥ 1 week, the number of dose delays and
number of dose reductions in INCT and CNCT. We will
also calculate the rate of grade 3 or higher adverse events
and surgical complications in each treatment arm.
In regard to Specific Aim 3, we will measure patient-
reported functional outcomes and QoL in patients with
LARC treated with NOM, compared to patients treated
with TME. The primary endpoint of QoL will be assessed
using the EQ-5D index, an overall measure of QoL and
health ranging from 0 (worst health) to 1 (best health).
Comparison will be done using the two-sample t-test. In
secondary analyses we will use a paired t-test to compare
the EQ-5D index, measured at 1 year, in patients with dur-
able NOM vs. TME. The differences in EQ-5D index from
1 year to 3 years will also be compared in patients with
durable NOM vs. TME, using an ANCOVA model.
The goal of Specific Aim 4 is to investigate the diag-
nostic performance of conventional MRI and DW-MRI
in identifying LARC patients treated with TNT who will
benefit from NOM. This will be the first study investi-
gating the diagnostic performance of conventional and
DW-MRI in LARC patients treated with TNT. There-
fore, this aim will be considered exploratory.
Patient selection and eligibility criteria
In order to participate, patients must have not received
previous chemotherapy, pelvic radiotherapy, or surgery
for their rectal cancer. Specific inclusion and exclusion
criteria are provided in Table 1. Biopsy confirmation of
the primary rectal tumor by pathology must be per-
formed at the participating institution before initiation
of therapy. Patients who choose to participate will pro-
vide written informed consent prior to study enrollment.
Patients will be recruited and consented in the Surgical
Colorectal clinics, Medical Oncology clinics and Radi-
ation Oncology clinics of participating institutions. Pa-
tients must undergo surgical, medical oncology and
radiation oncology evaluation at each participating site.
At baseline, each patient must undergo a full medical
history and physical examination, including assessment
of body weight, height, calculated body surface area and
sitting vital signs (blood pressure, heart rate, respiratory
rate, and temperature). Laboratory assessments include: a)
CBC with differential, comprehensive biochemical screen-
ing profile (electrolytes, BUN, creatinine, AST, ALT, total
bilirubin, total protein, albumin, alkaline phosphatase and
glucose); b) CEA; and c) urinalysis. Patients will undergo
baseline flexible sigmoidoscopy with a photograph of the
tumor, as well as biopsy, proctoscopy, ERUS and MRI of
the pelvis, to accurately assess the extent of the tumor. A
requirement for study entry is rectal cancer, clinically char-
acterized by evaluation with MRI as Stage II (T3-4, N0) or
Stage III (any T, N1-2) . For females of childbearing poten-
tial, a serum pregnancy test is also required. Additional
evaluations include baseline EKG and a signed informed
consent. CT scan of the chest and abdomen is required to
rule out disseminated metastatic disease. A PET scan will
be performed to assist in planning radiotherapy.
Histopathology and biospecimens
We will collect tumor and normal tissue samples at
baseline and during surgery in patients undergoing a
TME. We will also collect blood at baseline and at differ-
ent time points during and after treatment, to measure
circulating DNA and miRNA. Pathologic assessment of
the surgical specimens will be performed according to
the College of American Pathologists guidelines. Com-
pleteness of the mesorectal excision, tumor regression
grade (TRG), and tumor staging will be categorized ac-
cording to the criteria specified in the 7th Edition of the
AJCC Staging Manual [15].
Neoadjuvant treatment
The neoadjuvant chemotherapy regimen is prescribed
specifically as 8 cycles of FOLFOX or 6 cycles of
CapeOX over a period of approximately 16 weeks. The
CRT regimen consists of the standard MSK algorithms:
a total of 5600 cGy of radiation (4500 cGy to the pelvis,
with an integrated boost to the primary tumor and in-
volved nodes of 5000 cGy, followed by a 600 cGy boost
to the primary tumor and involved nodes) in 28 frac-
tions of 180-200 cGy each, over a 5-6-week period.
Starting on the first day of RT, patients receive 5-FU ad-
ministered by continuous infusion, or capecitabine, for
the duration of radiotherapy.
Evaluation of response and resectability
An interval evaluation will be conducted after com-
pletion of INCT in Arm 1, and after completion of
CRT in Arm 2 (Fig. 1). Patients in both arms will be
re-staged after completion of all neoadjuvant therapy.
Patients with cCR or near-complete clinical response
(Figs. 3 and 4) will be treated with NOM. Patients
treated with NOM will be followed every 3 months for
2 years, and every 6 months thereafter. Patients with
an incomplete response and residual tumor at the pri-
mary site will undergo a TME (see Fig. 5). Patients
treated with TME will be followed according to NCCN
guidelines [16,17].
Guidelines for tumor measurement
For the endoscopic exam, the length of the tumor is
defined as the difference between the distance of the
proximal and distal margins in relation to the anal verge.
For MRI/CT, the standard and DW-MRI sequences will
be obtained in 1.5 T or 3 T units by using a phased-
array body coil. All imaging studies will be interpreted
by expert radiology staff at the patient’s primary
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treatment center to determine patient eligibility, clinical
staging, and tumor response, according to standard clin-
ical criteria.
Criteria for response after neoadjuvant therapy
The primary tumor and the regional lymph nodes will
be evaluated and measured by endoscopic exam and
rectal MRI during re-staging. Central imaging review
will be performed by the Radiology PI at MSKCC after
receipt of baseline and post-TNT images. For quality
control purposes, baseline MRI images will be col-
lected for the first two patients enrolled at each site.
MRI images taken at interval evaluation are required
for all MSKCC patients, and are recommended for
participating sites. These interval evaluation images
will be submitted on disc for central review. All
Table 1 Inclusion and exclusion criteria for the trial
Inclusion Criteria Exclusion Criteria
General •Histologically confirmed diagnosis of adenocarcinoma
of the rectum
•Patients must have Stage II (uT3, uN0) or Stage III (T1-3, N1-3)
tum or, staged by MRI, that is potentially resectable
•Locally advanced rectal cancer a menable to total
mesorectal excision
•No evidence of distant metastases ·No prior pelvic radiation
therapy
•No prior chemotherapy or surgery for rectal cancer
•Age >18 years
•No infections requiring systemic antibiotic treatment
•Karnofsky >60% or ECOG 0-2 ·ANC > 1.5 cell/mm3,
Hgb>8.0 gm/ dL, PLT>150,000/mm3, total bilirubin < or equal
to 1.5 x upper limit of normal, AST > or equal to upper limit
of normal, ALT< or equal to three times upper limit of normal
•Recurrent rectal cancer
•Primary unresectable rectal cancer is defined as a
primary rectal tumor which, on the basis of either
physical examination or pelvic MRI, is deemed to
be adherent or fixed to adjacent pelvic structures.
(en bloc resection will not achieve negative margins)
•Serum creatinine level greater than 1.5 times the upper
limit of normal
•Patients who have received prior pelvic radiotherapy
•Patients with a history of any arterial thrombotic event
within the past 6 months, including angina (stable or unstable),
MI, or CVA
•Patients with any other concurrent medical or psychiatric
condition or disease which, in the investigator's judgment,
would make them inappropriate candidates for entry into
this study
•Patients with a history of a prior malignancy within the past
5 years, except for adequately treated basal cell or squamous
cell skin cancer, or in situ cervical cancer.
•Patients with a history of thrombotic episodes, such as deep
venous thrombosis, pulmonary embolus, MI, or CVA occurring
more than 6 months prior to enrollment may be considered for
protocol participation, provided they are on stable doses of
anticoagulant therapy. Patients who are anticoagulated for
atrial fibrillation or other conditions may participate, provided
they are on stable doses of anticoagulant therapy.
• Patients receiving other anticancer or experimental therapy.
No other experimental therapies (including chemotherapy,
radiation, hormonal treatment, antibody therapy, immunotherapy,
gene therapy, vaccine therapy, angiogenesis inhibitors, matrix
metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal
antibody, or other experimental drugs) of any kind are
permitted while the patient is receiving study treatment.
Consent Patients must read, agree to, and sign a statement of Informed
Consent prior to participation in this study. MSKCC patients
who do not read or understand English are eligible, but must
have the consent form read to them in its entirety by an
official translator, either from MSKCC or AT&T. Informed
consent for non-literate or non-English speaking patients
may not be obtained by using a relative or a member
of the patient’s clinical team as a translator. Consortium
sites must follow federal, local, and institutional regulations
to ensure that non-English speaking patients are consented
appropriately.
n/a
Women •Women with childbearing potential who are
negative for pregnancy test (urine or blood) and who
agree to use effective contraceptive methods.
A woman of childbearing potential is defined
by one who is biologically capable of becoming
pregnant. Reliable contraception should be used
from trial screening and must be continued
throughout the study.
Women who are pregnant or breastfeeding Women of childbearing
potential who are unwilling or unable to use an acceptable method
of birth control to avoid pregnancy for the entire study period, and
for up to 4 weeks after the study.
Men Male subjects must also agree to use effective contraception. n/a
Smith et al. BMC Cancer  (2015) 15:767 Page 7 of 13
submitted discs will be de-identified, labeled using the
unique study number, and in the DICOM format. MRI
images taken at re-staging will be collected for all pa-
tients, and sent to MSKCC on disc for central review.
Local and central interpretation will be tracked. Dis-
crepancies between clinical examination and imaging
will be resolved by the local investigator, but will be
communicated to the PI and Radiology PI at MSKCC.
In the event that the radiologist at MSKCC disagrees
with a site assessment, these discrepancies will be
relayed to local the PI and radiologist. No response
will be relayed to the participating site if, upon review
of submitted images, there are no discrepancies in as-
sessment. In general, clinical examination will prevail
over imaging in assessment of local tumor response.
Our regression schema, an online resource we have
Fig. 4 Near-complete response. Endoscopic and T2-weighted MRI images both pre- and post-treatment are shown for a patient who has
achieved a near complete response. This is a 74-year-old man who underwent 8 cycles of induction FOLFOX followed by CRT, and achieved a
near-cCR. A biopsy obtained in surveillance was determined to contain residual cancer; therefore, the patient was referred for TME
Fig. 3 Clinical complete response. Endoscopic and T2-weighted MRI images, both pre- and post-treatment, are shown for a patient who has
achieved a clinical complete response. Images displayed were taken from endoscopic and MRI views of an 85 year-old man who underwent
capecitabine CRT followed by consolidation chemotherapy with CapeOx and was determined to achieve cCR both clinically and radiologically.
In the post-treatment T2-weighted MRI image shown, the green arrow points to the prior site of the tumor
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created for all investigators, and the tabulated form
will be used to enhance uniformity of evaluation and
provide quantitative endpoints which we can use to
provide a more precise, consistent means of evaluating
assessment at the end of the study. Details of this
three-tiered response regression schema can be found
below (Table 2, and see below).
Treatment decisions after completion of TNT: The Memorial
Sloan Kettering Regression Schema
One of the main challenges to implementation of a
NOM protocol at a multi-institutional level is the
development of uniform and reproducible criteria for
tumor response. To that end, our consortium organized
a multidisciplinary videoconference on 26 January 2014
aimed at developing a consensus on the clinical criteria of
tumor response. The participants—colorectal surgeons,
medical oncologists, radiation oncologists, pathologists
and radiologists—elaborated a three-tiered assessment of
response/regression schema to differentiate between pa-
tients with a cCR who are therefore candidates for NOM,
from those without a cCR who are candidates for TME.
This regression schema was further discussed at the
American Society of Colon and Rectal Surgeons Annual
Fig. 5 . Incomplete response. Endoscopic and T2-weighted MRI images both pre- and post-treatment are shown for a patient who experienced
no significant response to induction chemotherapy followed by CRT. This is a 45-year-old woman who underwent 8 cycles of induction FOLFOX
followed by CRT with minimal or no response. The patient was therefore referred for TME
Table 2 Memorial Sloan Kettering Regression Schema
Complete Response Near Complete Response Incomplete Response





Small mucosal nodules or
minor mucosal abnormality
Superficial ulceration
Mild persisting erythema of the scar
Visible tumor
Digital Rectal Exam Normal Smooth induration or minor mucosal abnormalities Palpable tumor nodules
MRI-T2W Only dark T2 signal, no
intermediate T2 signal
Mostly dark T2 signal, some remaining
intermediate signal
More intermediate than dark T2
signal, no T2 scar
AND AND/OR AND/OR
No visible lymph nodes Partial regression of lymph nodes No regression of lymph nodes
MRI-DW No visible tumor on B800-B1000 signal Significant regression of signal on B800-B1000 Insignificant regression of signal
on B800-B1000
AND/OR AND/OR AND/OR
Lack of or low signal on ADC map
Uniform, linear signal in wall above
tumor is ok
Minimal or low residual signal on ADC map Obvious low signal on ADC
map
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Scientific Meeting in Hollywood, Florida in May 2014,
and finalized at the 2014 American College of Surgeons
Clinical Congress in October 2014. The regression schema
is presented in Table 2, and will be available online by
requesting access via Dr. Smith (smithj5@mskcc.org).
The regression schema is based on relatively subjective
endoscopic and radiological criteria and has not been
validated yet; however, it may provide some degree of
uniformity that may help to maintain consistency and
reduce variability between institutions.
Discussion
This study represents an attempt to investigate, in a
multi-institutional setting, the feasibility of rectal preser-
vation in a number of LARC patients who develop a
cCR after a novel neoadjuvant therapy protocol. It has
the potential to change the treatment paradigm for many
patients with rectal cancer. The study design is innova-
tive because it compares 3-year DFS in a group of LARC
patients treated according to a protocol incorporating
TNT and NOM, to a similar group of historical controls
treated according to the standard CRT, TME and ACT
protocol. The studies published thus far on the safety of
NOM in LARC patients have compared the survival of a
selected group of patients with a cCR and NOM, to a se-
lected group of patients with a pCR after TME. While
these reports provide an estimate of the safety of NOM,
they do not provide accurate information on the impact
of selective use of NOM on outcomes in the entire
LARC population. Our study will be the first to deter-
mine the proportion of patients with LARC who will be
candidates for NOM, and the impact of NOM on 3-year
DFS in the entire LARC population.
There is now conclusive evidence that tumor response
to chemotherapy and radiation requires time, and that
some tumors achieve a maximal response only after sev-
eral months. However, in the studies on NOM published
to date, tumor response was assessed a few weeks after
completing the standard neoadjuvant protocol. It is
possible that many patients who were considered non-
responders early on, and were therefore not offered
NOM, might actually have been complete responders
given a longer observation period. In our study, assess-
ment of tumor response is done only after all neoadju-
vant treatment is delivered. In patients completing the
entire treatment, final assessment of tumor respon-
se—and the decision between NOM and TME—will be
done approximately 32 weeks after initiation of therapy.
We think this will provide sufficient time for tumor
response.
In the past, LR, likely secondary to inadequate surgery,
was the most common form of relapse in patients with
LARC. Advances in imaging, surgical technique, and ad-
juvant therapy have reduced the risk of LR dramatically.
Nowadays patients with seemingly localized LARC who
die of disease after undergoing treatment with curative
intent, succumb to DM (which probably develops from
occult micrometastasis present at the time of treatment
of the primary tumor). Therefore, as in patients with
stage III colon cancer, current guidelines recommend
postoperative chemotherapy for patients with LARC.
While chemotherapy seems to improve survival com-
pared to no chemotherapy, it is not as effective as would
be desired. Although this may be due, in part, to the fact
that the agents used are not effective against every single
cancer, it is also the case that many rectal cancer pa-
tients never start chemotherapy after surgery, and less
than half complete the entire treatment [5,18]. In light
of our previous experience with neoadjuvant therapy, in
this study we will deliver all systemic chemotherapy be-
fore assessing tumor response. Delivering systemic
chemotherapy in the neoadjuvant setting will not only
improve compliance and address the problem of micro-
metastasis earlier, compared to the standard treatment
algorithm of CRT, TME and ACT; it may also contribute
to enhanced tumor response. As a result of lengthening
the treatment time by administering NACT, this study
will provide a closer estimate of the proportion of pa-
tients with LARC who will respond to chemotherapy
and radiation, and thus be eligible for NOM.
There are some potential advantages to using NACT
before or after CRT. Delivering NACT before CRT has
the advantage of treating occult micrometastasis earlier.
As the patients will be treatment naïve, compliance with
systemic CT may be higher. However, NACT-related
toxicity may potentially reduce compliance with CRT.
On the other hand, starting treatment with CRT delays
delivery of the full dose of systemic chemotherapy used
to treat micrometastatic disease, and this may reduce
compliance with NACT. An important question is which
treatment arm will demonstrate greater tumor response.
The results of the TIMING trial compared to the other
studies suggest that pCR rates are higher with CRT and
CNCT compared to INCT and CRT (see recent work in
The Lancet Oncology: PMID: 26187751). The differ-
ences between CRT and CNCT versus INCT and CRT
may be due to patient selection or delay in the time to
assessment of response, rather than treatment effect [9].
However, in patients with squamous cell carcinomas (of
various locations) undergoing neoadjuvant therapy, there
is evidence that longer duration of treatment, measured
from the first day of any therapy to the last day of radi-
ation, is associated with increased local failure and/or
decreased survival [19]. In anal cancer patients, overall
treatment time, but not radiotherapy time, is associated
with a high rate of local failure, suggesting that induction
chemotherapy may contribute to local failure by increasing
the total treatment time [20]. Our study will test this
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hypothesis to assess whether the same phenomenon
occurs in adenocarcinomas.
Patients with distal rectal cancer who require a CAA
as part of their surgical treatment also have a temporary
diverting loop ileostomy to reduce the risk of pelvic sep-
sis. Patients treated according to the standard protocol
of CRT, TME and ACT must live with a diverting loop
ileostomy for many months until they complete postop-
erative adjuvant chemotherapy. While the ileostomy is
effective in reducing major pelvic infections, it is an
inconvenience to the patient; it is also the source of
complications, such as dehydration and electrolyte im-
balances, which often require readmission to hospital
[21]. Delivering all systemic chemotherapy in the neoad-
juvant setting will shorten ileostomy time.
One of the main criticisms of NOM in patients with
LARC is the poor correlation between cCR (based on
both clinical examination and imaging studies) and pCR
to neoadjuvant therapy. However, response has typically
been assessed a few weeks after completion of neoadju-
vant therapy, before some tumors have achieved maximal
response, and before treatment-related tissue changes
have had an opportunity to subside. This will be the first
study to investigate the accuracy of clinical examination
and imaging studies in assessing tumor response after a
much longer treatment interval. It will also help validate a
set of predefined criteria regarding clinical and radio-
logical response(see Table 2).
Additionally, we will evaluate the feasibility of using
circulating tumor DNA and miRNA profiles in plasma,
to monitor tumor response to TNT, in rectal cancer pa-
tients treated in both of the protocol arms. Genomic
analysis by next-generation sequencing will be done to
profile rectal cancer treated with neoadjuvant chemo-
therapy and radiation. The separation of responders
from non-responders will facilitate investigation of the
molecular mechanisms of tumor resistance to neoadju-
vant therapy through genomic analysis of rectal cancer
before and after treatment. We think that this will lead
to more precise treatments of individual rectal cancer
patients based on the molecular profile associated with
each individual tumor.
In summary, this study will not only explore the feasi-
bility of NOM in a selected group of patients with LARC
who respond to neoadjuvant therapy. It will also provide
a wealth of information about the response of LARC to
chemotherapy and radiation. By delivering all adjuvant
therapy up front, we will be able to discriminate (or sep-
arate) responders from non-responders, determining the
real proportion of patients who will benefit from NOM,
facilitating the clinical and radiological identification of
responders, and facilitating molecular profiling. Finally,
the study will help determine the gains in QoL associ-
ated with organ preservation.
Overview of Clinical Trial 13-213 and summary
statements:
Herein we postulate that:
1. Delivery of chemotherapy before rather than after
surgery will improve survival, because it will treat
microscopic tumor deposits several months earlier,
will increase the proportion of patients completing
the entire treatment, and may reduce the size of the
primary tumor. This study will compare the two
different TNT regimens in two randomized
treatment arms. One treatment arm will receive
systemic chemotherapy before chemoradiation, and
the other treatment arm will receive it after
chemoradiation.
2. Delivery of chemotherapy before rather than after
surgery will shorten the amount of time before
ileostomy reversal. This study investigates the
feasibility and efficacy of delivering all adjuvant
treatment before surgery in LARC patients. Some
previous phase II trials have investigated the use of
chemotherapy before surgery in such patients, but
the chemotherapy delivered in these trials was only
a portion of that normally used after surgery. In this
study, we deliver all chemotherapy before surgery
(TNT). The results could be confirmed in a phase
III trial, and may represent the groundwork for a
paradigm shift in the treatment of rectal cancer.
3. Avoiding surgery selectively in patients with tumors
that respond to CRT will reduce over-treatment and
improve quality of life. The underlying theme here is
individualized treatment, tailored in a more precise
fashion. The potential gains for these patients in
terms of improved QoL will be significant. Over
20,000 new stage II and III rectal cancers are
diagnosed in the United States every year. Assuming
a 30 % rate of complete response, this could mean
that 6,000 patients will benefit from NOM, leading
to significant economic benefits and better QoL.
Proposed value-added contribution of this trial
This is the first prospective study investigating the
feasibility of NOM in rectal cancer patients who have
a complete response to neoadjuvant therapy. Add-
itionally, we will use the first regression schema to be
prospectively validated in a multi-institutional setting
for the assessment of response. We believe that the
proposed treatment will improve survival and pre-
serve QoL in LARC patients, in a more precise,
patient-centric manner.
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